Table 1 Participant baseline characteristics

From: Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

 

Nivolumab plus ipilimumab (n = 287)

Nivolumab (n = 320)

Durvalumab (n = 318)

Median age, years (range)

64 (33–85)

64 (37–92)

64 (32–84)

Male, n (%)

220 (77)

244 (76)

239 (75)

Geographic regiona, n (%)

North America

9 (3)

18 (6)

17 (5)

Europe

132 (46)

124 (39)

129 (41)

Asia

93 (32)

119 (37)

105 (33)

Rest of the world

53 (18)

59 (18)

67 (21)

ECOG PSb, n (%)

0

132 (46)

149 (47)

139 (44)

1

154 (54)

171 (53)

179 (56)

Disease stage IIIc, n (%)

IIIA

95 (33)

106 (33)

110 (35)

IIIB

128 (45)

143 (45)

141 (44)

IIIC

62 (22)

71 (22)

67 (21)

Histology, n (%)

Squamous

155 (54)

184 (58)

165 (52)

Nonsquamous

132 (46)

136 (42)

153 (48)

Smoking status, n (%)

Current/former

258 (90)

297 (93)

287 (90)

Never

24 (8)

21 (7)

30 (9)

Unknown

5 (2)

2 (1)

1 ( < 1)

Tumor PDL1 expression, n (%)

Not evaluable

22 (8)

24 (8)

30 (9)

<1%d

90 (31)

99 (31)

93 (29)

≥1%d

175 (61)

197 (62)

195 (61)

1–49%

92 (32)

89 (28)

98 (31)

≥50%

83 (29)

108 (34)

97 (30)

T stage, n (%)

T1

30 (10)

31 (10)

30 (9)

T2

28 (10)

47 (15)

45 (14)

T3

41 (14)

56 (18)

51 (16)

T4

185 (64)

186 (58)

186 (58)

Other/not reported

3 (1)

0

6 (2)

N stage, n (%)

N0

31 (11)

30 (9)

42 (13)

N1

28 (10)

24 (8)

27 (8)

N2

139 (48)

159 (50)

147 (46)

N3

87 (30)

106 (33)

95 (30)

Other/not reported

2 (1)

1 ( < 1)

7 (2)

  1. aA total of 30 participants from Russia were required to discontinue. bOne participant was considered ECOG PS 3 in the nivolumab plus ipilimumab arm. cTwo participants had stage IV cancer (one stage IVA and one stage IVB). dDenominator: tumor PDL1-quantifiable population.
  2. N, nodes; T, tumor.
Back to article page